These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 37019745)
41. CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis. Taylor-Cousar JL; Robinson PD; Shteinberg M; Downey DG Lancet; 2023 Sep; 402(10408):1171-1184. PubMed ID: 37699418 [TBL] [Abstract][Full Text] [Related]
42. Combination CFTR modulator therapy in children and adults with cystic fibrosis. Guimbellot JS; Taylor-Cousar JL Lancet Respir Med; 2021 Jul; 9(7):677-679. PubMed ID: 33965001 [No Abstract] [Full Text] [Related]
43. Ivacaftor for patients with cystic fibrosis. Wainwright CE Expert Rev Respir Med; 2014 Oct; 8(5):533-8. PubMed ID: 25148205 [TBL] [Abstract][Full Text] [Related]
44. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis. Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367 [TBL] [Abstract][Full Text] [Related]
45. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis. Cuyx S; De Boeck K Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727 [TBL] [Abstract][Full Text] [Related]
46. Reducing treatment burden in the era of CFTR modulators. Robinson PD; Douglas TA; Wainwright CE Lancet Respir Med; 2023 Sep; 11(9):e78. PubMed ID: 37321239 [No Abstract] [Full Text] [Related]
47. Overcoming health disparities in access to CFTR modulator therapies: One child's journey with cystic fibrosis. Januska MN; Langfelder-Schwind E; Berdella MN Pediatr Pulmonol; 2022 Sep; 57(9):2273-2275. PubMed ID: 35637164 [No Abstract] [Full Text] [Related]
48. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Rehman A; Baloch NU; Janahi IA N Engl J Med; 2015 Oct; 373(18):1783. PubMed ID: 26510035 [No Abstract] [Full Text] [Related]
49. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. Wainwright CE; Elborn JS; Ramsey BW N Engl J Med; 2015 Oct; 373(18):1783-4. PubMed ID: 26510034 [No Abstract] [Full Text] [Related]
51. Cystic Fibrosis-Related Pancreatic Cysts Decrease in Size and Number Upon Treatment With Cystic Fibrosis Transmembrane Conductance Regulator Modulators. de Vries JM; Green D; Kucera JN; Fabbrini AL; Kidder M; Brown J; Wilsey M Pancreas; 2020 Jul; 49(6):e50-e51. PubMed ID: 32590622 [No Abstract] [Full Text] [Related]
52. Cystic fibrosis transmembrane conductance regulator dysfunction and its treatment. Hull J J R Soc Med; 2012 Jun; 105 Suppl 2(Suppl 2):S2-8. PubMed ID: 22688363 [No Abstract] [Full Text] [Related]
53. Acute pancreatitis in pancreatic-insufficient cystic fibrosis patients treated with CFTR modulators. Sadras I; Cohen-Cymberknoh M; Kerem E; Koplewitz BZ; Simanovsky N; Wilschanski M; Birimberg-Schwartz L; Breuer O J Cyst Fibros; 2023 Jul; 22(4):777-779. PubMed ID: 36914434 [TBL] [Abstract][Full Text] [Related]
54. A combination therapy for cystic fibrosis. Brodsky JL; Frizzell RA Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363 [TBL] [Abstract][Full Text] [Related]
55. Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Derichs N Eur Respir Rev; 2013 Mar; 22(127):58-65. PubMed ID: 23457166 [TBL] [Abstract][Full Text] [Related]
56. Personalized medicine. New cystic fibrosis drug offers hope, at a price. Kaiser J Science; 2012 Feb; 335(6069):645. PubMed ID: 22323790 [No Abstract] [Full Text] [Related]
57. Cystic Fibrosis: The Dawn of a New Therapeutic Era. Heltshe SL; Cogen J; Ramos KJ; Goss CH Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011 [No Abstract] [Full Text] [Related]